Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Pulmonary Medicine
Published in: BMC Pulmonary Medicine 1/2020

Open Access 01-12-2020 | Systemic Lupus Erythematosus | Research article

Serum uric acid is associated with disease severity and may predict clinical outcome in patients of pulmonary arterial hypertension secondary to connective tissue disease in Chinese: a single-center retrospective study

Authors: Jingya Wang, Yuanyuan Wang, Xiaodi Li, Yingheng Huang, Xiaoxuan Sun, Qiang Wang, Miaojia Zhang

Published in: BMC Pulmonary Medicine | Issue 1/2020

Login to get access

Abstract

Background

Previous studies have shown that serum uric acid (UA) levels are correlated with the severity of idiopathic pulmonary arterial hypertension (IPAH) and are predictors of disease prognosis. Still, few studies have explored the value of serum UA in pulmonary arterial hypertension secondary to connective tissue disease (CTD-PAH). This retrospective study aimed to investigate the clinical value of serum UA levels in patients with CTD-PAH.

Methods

Fifty CTD-PAH patients were enrolled in our study, from which baseline UA levels, respective variations, and additional clinical data were collected. The potential association between baseline UA level and severity of CTD-PAH was investigated. Furthermore, the relationship between baseline UA and survival rate of CTD-PAH patients, as well as between UA variations and survival rate of pulmonary hypertension secondary to connective tissue disease (CTD-PH) patients was discussed.

Results

Baseline serum UA levels were positively correlated with pulmonary vascular resistance (PVR). During the follow-up period, 3 CTD-PAH and 12 CTD-PH patients died. Kaplan-Meier survival curves showed lower survival rate in patients with hyperuricemia than in patients with normouricemia, in both groups (CTD-PAH group p = 0.041, CTD-PH group p = 0.013). Concerning serum UA variations, patients with persistent hyperuricemia showed the lowest survival rate when compared with patients with steady normouricemia (p = 0.01) or patients with decresing serum UA levels, i.e. undergoing from a status of hyperuricemia to a status of normouricemia (p = 0.023).

Conclusion

Baseline serum UA levels might predict severity of CTD-PAH. Together with baseline values, changes of uric acid level may predict the clinical prognosis of the disease.
Appendix
Available only for authorised users
Literature
1.
Li M, Wang Q, Zhao J, Li Z, Ye Z, Li C, Li X, Zhu P, Wang Z, Zheng Y, et al. Chinese SLE treatment and research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus. Lupus. 2014;23(10):1085–91.PubMedCrossRef
2.
Aghdashi M, Behnemoon M, Mahmoodi RJ, Rabiepour M. Evaluation of serum uric acid level in systemic lupus erythematosus patients with normal and high pulmonary arterial hypertension. Biomedicine (Taipei). 2018;8(3):16.CrossRef
3.
Castillo-Martinez D, Marroquin-Fabian E, Lozada-Navarro AC, Mora-Ramirez M, Juarez M, Sanchez-Munoz F, Vargas-Barron J, Sandoval J, Amezcua-Guerra LM. Levels of uric acid may predict the future development of pulmonary hypertension in systemic lupus erythematosus: a seven-year follow-up study. Lupus. 2016;25(1):61–6.PubMedCrossRef
4.
Kim KJ, Baek IW, Park YJ, Yoon CH, Kim WU, Cho CS. High levels of uric acid in systemic lupus erythematosus is associated with pulmonary hypertension. Int J Rheum Dis. 2015;18(5):524–32.PubMedCrossRef
5.
Seyyedi SR, Menkmohammad M, Chitsazan M, Behzadnia N, Sadr M, Hashemian SM, Sharif-Kashani B. Relationship between Serum Uric Acid Levels and the Severity of Pulmonary Hypertension. Tanaffos. 2017;16(4):283–8.PubMedPubMedCentral
6.
Luo DL, Zhang CJ, Huang YG, Huang T, Li HZ. Serum uric acid is associated with disease severity and an important predictor for clinical outcome in patients with pulmonary hypertension. Zhonghua Xin Xue Guan Bing Za Zhi. 2017;45(6):496–500.PubMed
7.
Zhang CY, Ma LL, Wang LX. Relationship between serum uric acid levels and ventricular function in patients with idiopathic pulmonary hypertension. Exp Clin Cardiol. 2013;18(1):e37–9.PubMedPubMedCentral
8.
Li ZN, He JG, Liu ZH, Gu Q, Ni XH, Cheng XS, Xiong CM. Relationship between serum uric acid levels and patient conditions and prognosis in idiopathic pulmonary arterial hypertension. Natl Med J China. 2012;92(46):3261–4.
9.
Dimitroulas T, Giannakoulas G, Dimitroula H, Sfetsios T, Parcharidou D, Karvounis H, Settas L. Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study. Rheumatol Int. 2011;31(2):263–7.PubMedCrossRef
10.
Van Albada ME, Loot FG, Fokkema R, Roofthooft MT, Berger RM. Biological serum markers in the management of pediatric pulmonary arterial hypertension. Pediatr Res. 2008;63(3):321–7.PubMedCrossRef
11.
Jiang X, Han ZY, Wang Y, Xu XQ, Ma CR, Wu Y, Pan L, Jing ZC. Hemodynamic variables and clinical features correlated with serum uric acid in patients with pulmonary arterial hypertension. Chin Med J. 2008;121(24):2497–503.PubMedCrossRef
12.
Bendayan D, Shitrit D, Ygla M, Huerta M, Fink G, Kramer MR. Hyperuricemia as a prognostic factor in pulmonary arterial hypertension. Respir Med. 2003;97(2):130–3.PubMedCrossRef
13.
Nagaya N, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Nakanishi N, Yamagishi M, Kunieda T, Miyatake K. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med. 1999;160(2):487–92.PubMedCrossRef
14.
Kula S, Canbeyli F, Atasayan V, Tunaoglu FS, Oguz AD. A retrospective study on children with pulmonary arterial hypertension: A single-center experience. Anatol J Cardiol. 2018;20(1):41–7.PubMedPubMedCentral
15.
Wang LY, Lee KT, Lin CP, Hsu LA, Wang CL, Hsu TS, Ho WJ. Long-Term Survival of Patients with Pulmonary Arterial Hypertension at a Single Center in Taiwan. Acta Cardiol Sin. 2017;33(5):498–509.PubMedPubMedCentral
16.
Ozpelit E, Akdeniz B, Sezgin D, Sevinc C, Tertemiz KC, Ozpelit ME, Baris M, Baris N. Clinical and hemodynamic profiles of elderly patients with pulmonary arterial hypertension: a single center, prospective study. J Geriatr Cardiol. 2017;14(1):20–7.PubMedPubMedCentral
17.
Dhaun N, Vachiery JL, Benza RL, Naeije R, Hwang LJ, Liu X, Teal S, Webb DJ. Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: clinical associations. J Heart Lung Transplant. 2014;33(5):521–7.PubMedCrossRef
18.
Njaman W, Iesaki T, Iwama Y, Takasaki Y, Daida H. Serum uric Acid as a prognostic predictor in pulmonary arterial hypertension with connective tissue disease. Int Heart J. 2007;48(4):523–32.PubMedCrossRef
19.
Wensel R, Opitz CF, Anker SD, Winkler J, Hoffken G, Kleber FX, Sharma R, Hummel M, Hetzer R, Ewert R. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 2002;106(3):319–24.PubMedCrossRef
20.
Huang C, Li M, Liu Y, Wang Q, Guo X, Zhao J, Lai J, Tian Z, Zhao Y, Zeng X. Baseline Characteristics and Risk Factors of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients. Medicine (Baltimore). 2016;95(10):e2761.CrossRef
21.
Simpson CE, Damico RL, Hummers L, Khair RM, Kolb TM, Hassoun PM, Mathai SC. Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosis-related pulmonary arterial hypertension. Pulm Circ. 2019;9(3):2045894019859477.PubMedPubMedCentralCrossRef
22.
Naing P, Kuppusamy H, Scalia G, Hillis GS, Playford D. Non-invasive assessment of pulmonary vascular resistance in pulmonary hypertension: current knowledge and future direction. Heart Lung Circ. 2017;26(4):323–30.PubMedCrossRef
23.
Yan C, Xu Z, Jin J, Lv J, Liu Q, Zhu Z, Pang K, Shi Y, Fang W, Wang Y. A feasible method for non-invasive measurement of pulmonary vascular resistance in pulmonary arterial hypertension: combined use of transthoracic Doppler-echocardiography and cardiac magnetic resonance. Non-invasive estimation of pulmonary vascular resistance. Int J Cardiol Heart Vasc. 2015;9:22–7.PubMedPubMedCentral
24.
Zharikov S, Krotova K, Hu H, Baylis C, Johnson RJ, Block ER, Patel J. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol. 2008;295(5):C1183–90.PubMedPubMedCentralCrossRef
25.
Kang DH, Han L, Ouyang X, Kahn AM, Kanellis J, Li P, Feng L, Nakagawa T, Watanabe S, Hosoyamada M, et al. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol. 2005;25(5):425–33.PubMedCrossRef
26.
Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, Johnson RJ. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension. 2002;40(3):355–60.PubMedCrossRef
27.
Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13(12):2888–97.CrossRefPubMed
28.
Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26(2):269–75.PubMedCrossRef
29.
Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem. 1991;266(13):8604–8.PubMed
30.
Volkov AV, Iudkina NN, Nikolaeva EV, Kurmukov IA, Glukhova SI, Nasonov EL. Bosentan: a considerable increase in the survival of patients with pulmonary hypertension associated with systemic rheumatic diseases. Ter Arkh. 2014;86(5):32–9.PubMed
31.
Leberkuhne LJ, Ploegstra MJ, Douwes JM, Bartelds B, Roofthooft MT, Hillege HL, Berger RM. Serially Measured Uric Acid Levels Predict Disease Severity and Outcome in Pediatric Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2017;195(3):401–4.PubMed
32.
Zhao J, Wang Q, Liu Y, Tian Z, Guo X, Wang H, Lai J, Huang C, Yang X, Li M, et al. Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: a cohort study in China. Int J Cardiol. 2017;236:432–7.PubMedCrossRef
Metadata
Title
Serum uric acid is associated with disease severity and may predict clinical outcome in patients of pulmonary arterial hypertension secondary to connective tissue disease in Chinese: a single-center retrospective study
Authors
Jingya Wang
Yuanyuan Wang
Xiaodi Li
Yingheng Huang
Xiaoxuan Sun
Qiang Wang
Miaojia Zhang
Publication date
01-12-2020

Other articles of this Issue 1/2020

BMC Pulmonary Medicine 1/2020 Go to the issue

Research article

NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension

Research article

Clinical characteristics and outcomes in adult cystic fibrosis patients with severe lung disease in Porto Alegre, southern Brazil

Research article

Diagnostic procedure for idiopathic eosinophilic pleural effusion: a single-center experience

Research article

Impact of reducing the duration of antibiotic treatment on the long-term prognosis of community acquired pneumonia

Research article

Prognostic role of the preoperative neutrophil-to-lymphocyte ratio and albumin for 30-day mortality in patients with postoperative acute pulmonary embolism

Research article

Evidence synthesis in pulmonary arterial hypertension: a systematic review and critical appraisal
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits